SOURCE: Fresh Start Private Management Inc.

Fresh Start Private Management Inc.

April 20, 2011 06:30 ET

Fresh Start Private Signs Contract With Leading Health Insurance Company Aetna Health Management, LLC for Claims for Its Alcohol Treatment Day-Procedure

Terms of Contract Include Commitment for Prompt Payment From Insurance Company

LOS ANGELES, CA--(Marketwire - Apr 20, 2011) - Fresh Start Private (OTCBB: CEYY), a leader in the alcohol treatment and rehabilitation industry, announced that its alcohol treatment procedure has signed a contract with Aetna Health Management, LLC Individual and Family Plan Underwriting Department for the approval of its alcohol treatment program.

Aetna Health Management, Inc. operates as a subsidiary of Aetna Health Holdings, LLC and the Terms of contract include commitment for prompt payment from insurance company

Fresh Start Private continues to establish a successful business model that allows for its patients to be underwritten by their insurance providers; thereby increasing the market potential for its services to the 13.8 million Americans that have problems with drinking, including 8.1 million people who suffer from alcoholism. The number of patients treated for alcoholism is now approximately 950,000 annually.

And, as previously announced, FSP continues to work with Healthnet, Blue Cross, Kaiser, CIGNA, United Healthcare, Anthem, SSI, Blue Cross, Tri-West, MSI and Presbyterian to get more patients approved for treatment for its revolutionary Naltrexone implant.

A spokesperson commented, "Aggressive, eye-level marketing is now being followed by direct sales that include a mix of tactics including building partnerships and developing new sales leads. With revenue potentials of up to $120 million a clinic, our goal is to be become the leader in alcohol treatment in the United States."

About Fresh Start Private

Fresh Start Private is an alcohol addiction, alcohol withdrawal, alcohol abuse treatment and alcohol detox rehabilitation company on the leading edge of the alcohol addiction treatment. The Company has licensed a highly effective treatment delivers target therapeutic levels of Naltrexone that significantly reduce patients' cravings for alcohol. Please visit

Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "optimizing," "potential," "anticipate," "goal," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in Fresh Start filings with the Securities and Exchange Commission.

Contact Information

  • Investor Relations
    Bill Clayton
    Toll Free (877) 521-CEYY (2399)
    Email Contact